This inventor holds 1 USPTO granted patent. Top assignee: Exostemtech Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Jaehoon Sul: Innovator in Exosome Technology
Introduction
Jaehoon Sul is a prominent inventor based in Suwon-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic methods using exosomes.
Latest Patents
Jaehoon Sul holds a patent for an "Exosome comprising photocleavable protein, and use thereof." This patent describes an exosome that contains a fusion protein comprising a blue fluorescent protein (TagBFP), a photocleavable protein (mMaple3), and an exosome-specific marker protein (CD9). The invention demonstrates that when exposed to light of 405 nm, the photocleavable protein mMaple3 is cleaved, allowing the blue fluorescent protein to be delivered into target cells. Additionally, it has been found that Cre protein can be delivered into an animal organ when light is applied to an exosome containing the Cre fusion protein (Cre-mMaple3-CD9). This innovative approach is expected to enhance the field of protein treatment by enabling the safe and efficient delivery of therapeutic proteins into cells.
Career Highlights
Jaehoon Sul is associated with Exostemtech Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, particularly in the application of exosome technology for therapeutic purposes.
Collaborations
Some of Jaehoon Sul's notable coworkers include Dong Gyu Jo and Jihoon Han. Their collaborative efforts contribute to the innovative research being conducted at Exostemtech Co., Ltd.
Conclusion
Jaehoon Sul's contributions to exosome technology represent a significant advancement in the field of biotechnology. His innovative patent and ongoing research efforts are paving the way for new therapeutic applications that could greatly benefit medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile